Mesoblast Ltd: Class Action Resolution
Mesoblast Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Mesoblast Ltd: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
Mesoblast Ltd: Confirmatory Phase 3 Back Pain Trial Actively Enrols
Mesoblast Ltd: Appendix 3Y for Philip Krause
Mesoblast Ltd: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
Mesoblast Ltd: Mesoblast to File BLA for Ryoncil FDA Approval Next Week
Mesoblast Ltd: Mesoblast Corporate Presentation at Investor Conference
Mesoblast Ltd: Appendix 3Y for Eric Rose
Mesoblast Ltd: Appendix 3Y for Eric Rose
Mesoblast Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Mesoblast Ltd: Mesoblast Chair Transition
Mesoblast Ltd: Appendix 3Y for Jane Bell
Mesoblast Ltd: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
Mesoblast Ltd: Pause in Trading
Mesoblast Ltd: FDA Supports Accelerated Approval Pathway for Heart Failure
Mesoblast Ltd: Mesoblast 2024 Half Year Financial Results Webcast
Mesoblast Ltd: FDA Grants Orphan Drug Designation for Revascor
Mesoblast Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Mesoblast Ltd: FDA Grants Rare Pediatric Disease Designation for Revascor
No Data